Zhang, Peiling
Yang, Xiuxiu
Cao, Yang
Wang, Jue
Zhou, Mi
Chen, Liting
Wei, Jia
Mao, Zekai
Wang, Di
Xiao, Yi
Zhu, Haichuan
Zhang, Shangkun
Zhang, Tongcun
Zhang, Yicheng
Zhou, Jianfeng
Huang, Liang
Funding for this research was provided by:
National Natural Science Foundation of China (81830008, 82070211)
National High Technology Research and Development Program of China (863 program 2014AA020532)
Milstein Medical Asian American Partnership Foundation (2018 MMAAP Foundation Hematology Fellowship Award)
Young Top-notch Talent Cultivation Program of Hubei Province
Article History
Received: 15 August 2022
Accepted: 19 September 2022
First Online: 17 October 2022
Declarations
:
: This study was conducted in compliance with the principles of the Declaration of Helsinki. Ethics approval from the Institutional Review Board of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, was obtained before the start of the study. Written informed consent was obtained from all participants. This trial was registered in the Chinese Clinical Trial Registry (ChiCTR, number ChiCTR2100053662).
: Written informed consent for publication was obtained.
: Authors H.Z., S.Z., and T.Z. were employed by Wuhan Bio-Raid Biotechnology Co., Ltd.. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.